Cingulate Therapeutics said this week that it began a proof-of-concept trial for its controlled-release attention deficit/hyperactivity disorder drug. The 4-week clinical trial is being conducted by its development partner, Bio-Images Drug Delivery.

The trial enrolled healthy volunteers to evaluate the pharmacokinetic behavior of CTX-1301, including the body’s absorption, distribution, metabolism and excretion of the drug. The drug uses multi-core, timed-release technology to last the entire active day and minimize the patient’s “crashing” feeling in the afternoon, according to the company.

Get the full story at our sister site, Drug Delivery Business News.